Vertex Pharmaceuticals Inc. (VRTX)

159.19
NASDAQ : Health Technology
Prev Close 156.57
Day Low/High 155.76 / 160.28
52 Wk Low/High 125.50 / 178.25
Avg Volume 1.50M
Exchange NASDAQ
Shares Outstanding 254.83M
Market Cap 39.90B
EPS 1.10
P/E Ratio 182.06
Div & Yield N.A. (N.A)

Latest News

Vertex Opens Expanded Research Site In San Diego

Vertex Opens Expanded Research Site In San Diego

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the opening of its new 170,000 square foot research facility in Torrey Pines, San Diego.

Vertex Announces Long-Term Access Agreement In Sweden For Cystic Fibrosis Medicine ORKAMBI® (lumacaftor/ivacaftor)

Vertex Announces Long-Term Access Agreement In Sweden For Cystic Fibrosis Medicine ORKAMBI® (lumacaftor/ivacaftor)

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that ORKAMBI ® (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF) in people with two copies of the F508del mutation, ages six and older, will...

The Vertex Foundation And Employees Donate $1 Million Through Matching Gift Program

The Vertex Foundation And Employees Donate $1 Million Through Matching Gift Program

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Vertex employees and The Vertex Foundation have together donated over $1 million through the Company's new dollar-for-dollar matching gift program.

Vertex Data Presented At European Cystic Fibrosis Society (ECFS) Conference Demonstrate Early And Long-Term Disease-Modifying Potential Of Treating The Underlying Cause Of CF

Vertex Data Presented At European Cystic Fibrosis Society (ECFS) Conference Demonstrate Early And Long-Term Disease-Modifying Potential Of Treating The Underlying Cause Of CF

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced 10 scientific abstracts from the company's portfolio of cystic fibrosis (CF) medicines are being presented at the 41 st European Cystic Fibrosis Conference taking place June 6-9, 2018, in...

Vertex To Present At The Goldman Sachs Healthcare Conference On June 13

Vertex To Present At The Goldman Sachs Healthcare Conference On June 13

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference on Wednesday, June 13, 2018 at 5:40 p.

2 Trading Opportunities in Health Care

2 Trading Opportunities in Health Care

The potential of these setups on the weekly chart is rather good.

Vertex Awards $400,000 In Scholarships To People Living With Cystic Fibrosis And Their Immediate Family Members

Vertex Awards $400,000 In Scholarships To People Living With Cystic Fibrosis And Their Immediate Family Members

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the recipients of scholarships as part of its second All in for CF Scholarship program.

Vertex Reports First-Quarter 2018 Financial Results

Vertex Reports First-Quarter 2018 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2018 and reviewed recent progress with its approved and investigational medicines.

VX-445 Phase 3 Clinical Trial Program Overview

VX-445 Phase 3 Clinical Trial Program Overview

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it is initiating two Phase 3 studies of VX-445, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis (CF).

Sarepta Hit With Call to Drop Duchenne Drug Costs

Sarepta Hit With Call to Drop Duchenne Drug Costs

The biopharmaceutical company, which won controversial FDA approval for a Duchenne Muscular Dystrophy drug, now confronts patient groups asking HHS to take its patents and drop the price of that drug.

Vertex Appoints Kimberly A. White As Senior Vice President And Chief Communications Officer

Vertex Appoints Kimberly A. White As Senior Vice President And Chief Communications Officer

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Kimberly A.

Trying the Long Side of Vertex's Stock Again

Trying the Long Side of Vertex's Stock Again

After pharmaceutical company breaks out, charts suggest now is the time to go back in.

Vertex To Present At The Cowen Healthcare Conference On March 13

Vertex To Present At The Cowen Healthcare Conference On March 13

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Healthcare Conference on Tuesday, March 13, 2018 at 12:00 p.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: GTLS, JWN, SBLK, SSW, VRTX Downgrades: ACU, AFH, BKS, CRAY, MATX, MEI, NYLD.A, OPHT Initiations: WAAS Read on to get TheStreet Quant Ratings' detailed report:

20 Stock Picks to Weather Any Storm From Trade Wars to Fed Rate Hikes

20 Stock Picks to Weather Any Storm From Trade Wars to Fed Rate Hikes

Worry abounds on Wall Street this week. Do you know which stocks have the lowest exposure to developments from Washington?

VX-659 Phase 3 Clinical Trial Program Overview

VX-659 Phase 3 Clinical Trial Program Overview

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it is initiating a Phase 3 study of VX-659, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic...

Vertex Appoints Reshma Kewalramani, M.D., As Chief Medical Officer

Vertex Appoints Reshma Kewalramani, M.D., As Chief Medical Officer

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Reshma Kewalramani, M.

Vertex Initiates First Phase 3 Study Of VX-659, Tezacaftor And Ivacaftor As A Triple Combination Regimen For People With Cystic Fibrosis

Vertex Initiates First Phase 3 Study Of VX-659, Tezacaftor And Ivacaftor As A Triple Combination Regimen For People With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it is initiating the first Phase 3 study of VX-659, tezacaftor and ivacaftor as an investigational triple combination regimen for people with...

Vertex Announces Treatment With The NaV1.8 Inhibitor VX-150 Showed Significant Relief Of Acute Pain In Phase 2 Study

Vertex Announces Treatment With The NaV1.8 Inhibitor VX-150 Showed Significant Relief Of Acute Pain In Phase 2 Study

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results of a Phase 2 study of the NaV1.

SYMDEKO (Photo: Business Wire)

SYMDEKO (Photo: Business Wire)

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Vertex Pharmaceuticals, Amgen and Johnson and Johnson were among the big movers in the biotech and pharmaceutical sectors.

Vertex Selects Two Next-Generation Correctors, VX-659 And VX-445, To Advance Into Phase 3 Development As Part Of Two Different Triple Combination Regimens For People With Cystic Fibrosis

Vertex Selects Two Next-Generation Correctors, VX-659 And VX-445, To Advance Into Phase 3 Development As Part Of Two Different Triple Combination Regimens For People With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the selection of two next-generation correctors, VX-659 and VX-445, to advance into Phase 3 development as part of two different triple combination...

Vertex Reports Full-Year And Fourth-Quarter 2017 Financial Results

Vertex Reports Full-Year And Fourth-Quarter 2017 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year and fourth quarter ended December 31, 2017.

Vertex Selects Two Next-Generation Correctors, VX-659 And VX-445, To Advance Into Phase 3 Development As Part Of Two Different Triple Combination Regimens For People With Cystic Fibrosis

Vertex Selects Two Next-Generation Correctors, VX-659 And VX-445, To Advance Into Phase 3 Development As Part Of Two Different Triple Combination Regimens For People With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the selection of two next-generation correctors, VX-659 and VX-445, to advance into Phase 3 development as part of two different triple combination...

Vertex Receives EU Approval For ORKAMBI® (lumacaftor/ivacaftor) In Children With Cystic Fibrosis Ages 6-11 With Two Copies Of The F508del Mutation

Vertex Receives EU Approval For ORKAMBI® (lumacaftor/ivacaftor) In Children With Cystic Fibrosis Ages 6-11 With Two Copies Of The F508del Mutation

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted extension of the Marketing Authorization for ORKAMBI ® (lumacaftor/ivacaftor), the first medicine to...

Feed the Beast: Cramer's 'Mad Money' Recap (Thursday 1/4/18)

Feed the Beast: Cramer's 'Mad Money' Recap (Thursday 1/4/18)

Jim Cramer says this beast of a bull market is getting a steady diet of healthful sector opportunities.

Cramer: 2017 Was a Year of Resurrection and Revival

Cramer: 2017 Was a Year of Resurrection and Revival

Look no further than the top 10 winners in the S&P 500 and you will see just what I mean.

Vertex Announces Upcoming Presentation At The J.P. Morgan Healthcare Conference And Date Of Fourth-Quarter And Full-Year 2017 Financial Results

Vertex Announces Upcoming Presentation At The J.P. Morgan Healthcare Conference And Date Of Fourth-Quarter And Full-Year 2017 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.

TheStreet Quant Rating: B- (Buy)